Research in IMO
Ongoing projects
iPS cells as a study tool and model to implement the CRISPR-Cas system in the treatment of Retinal Dystrophies
The ultimate goal of this research is to lay the foundation for the application of cell therapy in the treatment of retinal dystrophies, by implanting healthy cells, obtained from iPS cells, in the patients' affected tissues.
PRGF-Endoret
Randomised, parallel-group, multicentre, blind to evaluators clinical trial to assess the efficacy and safety of PRGF-Endoret eye drops in patients with stage 2 and 3 neurotrophic keratitis.
IN-SIGHT
Efficacy and safety assessment of T4032 (unpreserved bimatoprost 0.01%) versus Lumigan 0.01% in ocular hypertensiove or glacomatous patients
Project history
Mass sequencing of exomes for the identification of new genes and variants responsible for retinal dystrophies
Retinitis pigmentosa, with a prevalence of 1 in 4,000 people and more than one million sufferers worldwide, is the most common retinal dystrophy. These diseases are neurodegenerative and caused by the death of the photoreceptors and cells of the retinal pigment epithelium.
EFOS
Clinical trial to evaluate the effects of Fydrane® and standard topical mydriatics and anaesthetics protocol on ocular surface after cataract surgery.